Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, announced first patient treated with imlifidase in an investigator-initiated phase 2 study in anti-neutrophil cytoplasmic antibody -associated vasculitis.
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, announced first patient treated with imlifidase in an investigator-initiated phase 2 study in anti-neutrophil cytoplasmic antibody -associated vasculitis.